Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant S-1 + cisplatin + docetaxel for large type 3 or type 4 gastric cancer (OGSG1402)
jRCTs051180195Phase 2Completed
- Start
- Mar 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur, cisplatin and docetaxel in gastric cancer (GC). Primary endpoint: R0 resection rate. Started Mar 2015; status: completed.
02
Drugs
tegafurcisplatindocetaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on jRCTs051180195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180195.